Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study

被引：0
|
作者：
Gardner, Thomas A.
Petrylak, Daniel Peter
Corman, John M.
Hall, Simon
Weinstein, Ralph
Keyser, Robert
Sims, Robert Brownell
Sanders, Amanda
Sheikh, Nadeem A.
Higano, Celestia S.
机构：
[1] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Columbia Univ, Med Ctr, New York, NY USA
[3] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[4] Mt Sinai Sch Med, New York, NY USA
[5] US Oncol, Portland, OR USA
[6] Dendreon Corp, Seattle, WA USA
[7] Univ Washington, Sch Med, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
148
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).
    Quinn, David I.
    Freedland, Stephen J.
    Heath, Elisabeth I.
    Tutrone, Ronald F.
    McLeod, David G.
    Sheikh, Nadeem Anwar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [42] Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
    Kantoff, Philip W.
    Higano, Celestia S.
    Small, Eric J.
    Whitmore, James B.
    Frohlich, Mark W.
    Schellhammer, Paul F.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (14) : 1107 - 1109
  • [43] The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
    Zhang, Li
    Sinha, Meenal
    Subudhi, Sumit Kumar
    Chen, Brandon
    Marquez, Jaqueline
    Liu, Eric
    Allaire, Kathryn
    Cheung, Alexander
    Ng, Sharon
    Nguyen, Christopher
    Friedlander, Terence W.
    Aggarwal, Rahul Raj
    Spitzer, Matthew
    Allison, James Patrick
    Small, Eric Jay
    Sharma, Padmanee
    Fong, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC).
    Quinn, David I.
    Drake, Charles G.
    Dreicer, Robert
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Corman, John M.
    Concepcion, Raoul S.
    Pieczonka, Christopher Michael
    Chang, Nancy N.
    DeVries, Todd
    Sheikh, Nadeem A.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Borxpten: A phase II study of bortezomib (B) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with PTEN deletion.
    Thomas, Vinay Mathew
    Moynier, Colin
    Boucher, Kenneth M.
    Nordblad, Blake
    Clement, Susan
    Esplin, Michelle
    Kohli, Manish
    Gupta, Sumati
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS258 - TPS258
  • [46] SIPULEUCEL-T (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES
    Corman, John
    Petrylak, Daniel P.
    Drake, Charles G.
    Pieczonka, Christopher M.
    Karsh, Lawrence I.
    Concepcion, Raoul S.
    Garcia, Jorge A.
    Dunshee, Curtis J.
    Van Mouwerik, Tim
    Tyler, Robert C.
    Chang, Nancy N.
    Quinn, David I.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E306 - E307
  • [47] Clonotypic T-cell responses in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with standard sipuleucel-T (sip-T) compared with patients receiving a booster treatment.
    Zhang, Li
    Kandadi, Harini
    Paciorek, Alan T.
    He, Tao
    Sheikh, Nadeem Anwar
    Fong, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [48] Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy
    Wei, Xiao X.
    Perry, Jaselle
    Chang, Emily
    Zhang, Li
    Hiatt, Robert A.
    Ryan, Charles J.
    Small, Eric J.
    Fong, Lawrence
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : 184 - +
  • [49] Time to next line therapy after initiation of sipuleucel-T in metastatic castration-resistant prostate cancer patients.
    Luu, Dai
    Goldstein, Leanne
    Twardowski, Przemyslaw
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
    Holl, Eda K.
    McNamara, Megan A.
    Healy, Patrick
    Anand, Monika
    Concepcion, Raoul S.
    Breland, Coleman D.
    Dumbudze, Igor
    Tutrone, Ron
    Shore, Neal
    Armstrong, Andrew J.
    Harrison, Michael
    Wallace, Joe A.
    Wu, Yuan
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (04) : 588 - 592
12345